α2 agonist slows retinal dystrophy progression

Article

Patients with retinal dystrophy experience slower disease progression when treated with the α2 agonist brimonidine, according to a study published in the February 2008 issue of the Journal of Ocular Pharmacology and Therapeutics.

Patients with retinal dystrophy experience slower disease progression when treated with the α2 agonist brimonidine, according to a study published in the February 2008 issue of the Journal of Ocular Pharmacology and Therapeutics.

Saul Merin and team, from the Hadassah-Hebrew University Medical Center, Israel, assessed the neuroprotective effect of the topical agent in 26 patients with retinal dystrophies. One randomly selected eye was treated with brimonidine tartrate 0.2% twice-daily, while the fellow eye received artificial tears. Disease progression parameters tested at six to eight-month intervals throughout the study included Goldmann visual fields, contrast sensitivity, colour vision, and fullfield electroretinography.

Seventeen patients completed the study. At the conclusion, there were no differences detected in visual acuity, colour vision, and contrast sensitivity between the treated and control eyes. There was a trend, however, toward a lesser degree of visual field loss (VFL) in the brimonidine-treated eyes, and a delay in the time required to reach a 25% VFL in the treated eyes. These differences were more pronounced in a subgroup of patients diagnosed with retinitis pigmentosa and with visual fields of 5 cm2 or more at baseline.

The team concluded that there is a trend for slower disease progression in the eyes of patients with retinal dystrophy when treated with brimonidine.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.